Human Genome Returning 13% With Bet on Glaxo Sweetener

Human Genome Sciences Inc. investors betting on a sweetened bid from GlaxoSmithKline Plc stand to reap a 13 percent return, even as their expectations of securing America’s biggest price increase diminish.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.